Geneva, 6 February, 2020: IFPMA welcomes a renewed immunization strategy, supporting Heads of States’ commitment to “accelerate efforts towards the achievement of UHC by 2030 to ensure healthy lives and promote well-being for all throughout the life-course”. IFPMA supports SAGE recommendations, in particular integration between disease-elimination initiatives and national immunization programs as achieved in “Defeating...
Read moreThis article was originally published in STAT News on February 5, 2020. As the number of people infected with the novel coronavirus 2019-nCoV increases each day, scientists around the world are racing to find a treatment. Since the virus was first reported from Wuhan, China, at the end of December, and the declaration of a public health...
Read moreDelivered by David Gleicher (MSD) as part of the UHC 2030 Private Sector Constituency Geneva, 5 February, 2020: Universal Health Coverage means that all individuals and communities have access to quality essential health services without risk of financial hardship. The private sector is well-positioned to contribute to UHC efforts and already provides health products and...
Read moreDelivered by Vanessa Peberdy, Head of NCD Policy & Advocacy & WHO Engagement Geneva, 4 February 2020: This Statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association, the Global Self-Care Federation, supported by the International Council of Biotechnology Associations. We represent key...
Read moreThe Ethos of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is centered on trust to “act with integrity and honesty to improve patient care and build trust with those we serve and to respect the independence of healthcare providers, patients and other stakeholders”. The purpose of this document is to provide additional interpretation...
Read moreGeneva, 31 January 2020: The research-based biopharmaceutical industry (IFPMA and its members) is deeply concerned by the coronavirus (2019-nCoV acute respiratory disease) epidemic. Outbreaks of novel virus infections for which there is no known effective antiviral therapy present a serious threat to public health. IFPMA and its members stand together in support with the global...
Read moreG-FINDER report: Investment in neglected disease R&D by multinational pharmaceutical companies grew by more than a quarter in 2018, reaching its highest-ever level Geneva, 30 January 2020: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 2019 G-FINDER report, which tracks public, private and philanthropic investment into product R&D for neglected diseases. The report shows...
Read moreThis article was originally published in Life Science Leader on January 29, 2020. A staggering 1.5 billion people, each year, are treated for a neglected tropical disease (NTDs). These diseases can be painful, blinding and disfiguring, keeping children out of school and adults out of work, are often attached to stigma in some community. These diseases are...
Read moreThis year IFPMA is hosting its 10th Asia Regulatory Conference (ARC2020) in Kuala Lumpur. The Council for International Organizations of Medical Sciences (CIOMS) is represented in the conference Advisory Board by Dr Lembit Rägo, its Secretary General. IFPMA sat down with Dr Rägo to discuss CIOMS’s activities, future of the biopharmaceutical industry and the future...
Read moreAMR Industry Alliance reports breakthroughs in the responsible manufacturing of antibiotics and positive steps to improve how patients access and use antibiotics. But its report also highlights concerning levels of research and development (R&D) investment. Alliance records US$6bn annual investment (in 2018) in antimicrobial resistance (AMR)-relevant R&D. Concerning shortfall is in late stage R&D investment...
Read moreThis article was originally published in Pharma Focus Asia in December 2019. Regulatory reliance is increasingly being used by National Regulatory Authorities (NRAs) with different regulatory systems and is actively promoted by the World Health Organization (WHO) as a mechanism to better manage resource capacity issues and strengthen regulatory systems. NRAs in Asia remain key...
Read more